To address the national shortage of surgical oncology clinician-investigators, the Department of Surgical Oncology at the University of Texas M. D. Anderson Cancer Center has dedicated its T32 training program to producing academic surgical oncologists. This goal is being met by developing in our T32 trainees the research background skills necessary to be a productive surgical investigator. Moreover, we are committed to providing T32 training to groups that are underrepresented in academic surgical oncology, including minority individuals and women. Our T32 program provides research opportunities in a broad range of basic oncologic disciplines, including tumor biology, oncogene and tumor suppressor gene biology, signal therapeutics and other cancer-related research areas. In addition, we recently reincorporated the option for T32 fellows to obtain training in """"""""clinical effectiveness"""""""" while still obtaining didactic training in basic science research. This training broadens the education of all trainees through our conference structure. This versatility in academic training increases the likelihood of obtaining an academic position upon completion of training. Training in biostatistics and the responsible conduct of research, and a rich array of seminars and graduate courses are integral to this T32 program. Training is offered to postdoctoral M.D. fellows either during a 24-month hiatus from General Surgery residency or during a two to three-year fellowship in Surgical Oncology that begins after General Surgery residency. Upon completion of training almost all (94%) T32 trainees have either entered Surgical Oncology fellowships or geographic full time academic Surgical Oncology positions. The T32 program faculty includes surgical investigators and full-time academic basic science researchers, all of whom have peer-reviewed grant support. The University of Texas M. D. Anderson Cancer Center vigorously promulgates a core mission excellence in research, education, and patient care. As a result, this is a highly stimulating environment in which aspiring academic surgical oncologists can receive research training under the aegis of the T32 program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009599-24
Application #
8214580
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
1994-05-25
Project End
2013-03-31
Budget Start
2012-02-01
Budget End
2013-03-31
Support Year
24
Fiscal Year
2012
Total Cost
$350,884
Indirect Cost
$37,749
Name
University of Texas MD Anderson Cancer Center
Department
Surgery
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Prieto, Peter A; Reuben, Alexandre; Cooper, Zachary A et al. (2016) Targeted Therapies Combined With Immune Checkpoint Therapy. Cancer J 22:138-46
Kang, Ya'an; Roife, David; Lee, Yeonju et al. (2016) Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Clin Cancer Res 22:4934-4946
Bhattacharya, Rajat; Ye, Xiang-Cang; Wang, Rui et al. (2016) Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer Res 76:3014-24
Alawadi, Zeinab; Phatak, Uma R; Hu, Chung-Yuan et al. (2016) Comparative effectiveness of primary tumor resection in patients with stage IV colon cancer. Cancer :
Chen, Pei-Ling; Roh, Whijae; Reuben, Alexandre et al. (2016) Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6:827-37
Roife, David; Dai, Bingbing; Kang, Ya'an et al. (2016) Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 22:6021-6030
Chawla, Akhil; Alatrash, Gheath; Philips, Anne V et al. (2016) Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunol Immunother 65:741-51
San Lucas, F A; Allenson, K; Bernard, V et al. (2016) Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol 27:635-41
McAuliffe, Priscilla F; Evans, Kurt W; Akcakanat, Argun et al. (2015) Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One 10:e0136851
Voss, Rachel K; Cromwell, Kate D; Chiang, Yi-Ju et al. (2015) The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol 112:834-40

Showing the most recent 10 out of 161 publications